Dr. Feng Lin has 17 years of experience in the fields of immunotherapy and cell therapy. His journey has been marked by leadership roles in new product development and commercial functions within prominent biotech companies. Having led diverse teams, Dr. Lin has played a crucial role in the development of antibody drugs and immune cell therapies, both in preclinical and clinical settings. His approach reflects a commitment to advancing therapeutic interventions and contributing to the forefront of biomedical research. Dr. Lin’s academic foundation was established at the Central South University Xiang-Ya School of Medicine in Changsha, China, where he earned a Ph.D. in Hematology and Physiology. Complementing this, he holds an M.Sc. in Biochemistry and Molecular Biology and an M.D. in Medicine.​